Courses

Title

Category

Credits

Event date

Cost

AMA PRA Category 1 Credit™
Ethics
Participation

$0.00

This two part video series explores the unique aspects of caring for children and adolescents. Issues like decision making, consent and assent, and confidentiality and privacy are discussed.

Module 10: Impaired Physicians

AMA PRA Category 1 Credit™
Ethics
Participation

$0.00

This two part video series addresses issues surrounding disruptive or impaired members of the care team. It defines the problem in terms of clinicians’ professional obligations and culture, and explores possible causes for these types of behavior. Finally, it identifies strategies for managing disruption or impairment in colleagues and in one’s self.

Module 8: Healthcare Economics

AMA PRA Category 1 Credit™
Ethics
Participation

$0.00

In this two-part video presentation, you will learn about the history of insurance in the United States, different healthcare payment systems, moral hazard and adverse selection, and how healthcare resources are allocated.

Module 7: Clinical Decision Making

AMA PRA Category 1 Credit™
Ethics
Participation

$0.00

In this three part video presentation, you will learn about the legal and ethical purposes of informed consent and shared decision making. You will also learn techniques to engage in shared decision making.

Module 11: Research Ethics

AMA PRA Category 1 Credit™
Ethics
Participation

$0.00

This two-part video series addresses issues surrounding the ethics of human subject research. The difference between quality improvement and research ethics. The history of biomedical research is addressed.

Module 14: Navigating End-of-Life

AMA PRA Category 1 Credit™
Ethics
Participation

$0.00

This two-part video series addresses issues surrounding the ethics end-of-life care. It provides guidance for providers to discuss end-of-life issues with patients that are health and patients who are terminal. Tips for discussing end-of-life with patient’s families are provided.

Achieving Data Quality and Integrity in Maximum Containment Laboratories

AMA PRA Category 1 Credit™
ANCC
Attendance

06/14/2021

$0.00

OverviewTo protect our Nation’s security, medical countermeasures must be developed to treat and prevent infections with microorganisms that threaten our Nation’s health. Fourteen years ago the United States Department of Health and Human Services Food and Drug Administration (FDA) published the final rule for New Drug and Biological Drug Products; Evidence needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible (21 CFR Parts 314 and 601, Federal Register, May 31, 2002).

Treating Acute Myeloid Leukemia in Resource-Limited Settings: Leveraging Lessons from the Past to Move Forward